Zilurgisertib fumarate is under clinical development by Incyte and currently in Phase II for Multiple Myeloma (Kahler Disease).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Players, coaches, and families gathered in North Charleston Saturday for a benefit game in honor of Oceanside basketball ...

Oncologist David Chung is taking on Northwell Health's newly established role of director of clinical research at its cancer ...

Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...

The following is a summary of “Impact of liquid–liquid phase separation- and immune-related gene signatures on multiple ...

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow ...

Northwell Health invests $19 million into a new 11-bed bone marrow transplant unit aiming to increase its market share.

It’s definitely progress.” Autologous transplants have also dropped for multiple myeloma, but only a little, according to ...

Forty-eight patients with multiple myeloma, most of them ambulatory outpatients, at 5 co-operating hospitals,‡ were treated. Patients were entered in the double-blind study by randomized card ...

For patients with functional high-risk multiple myeloma, timely referral to specialized centers is needed, since access to ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...